News

DelveInsight’s analysis forecasts Parkinson’s disease market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated ...
This milestone is a testament to King’s College Hospital Dubai’s unwavering dedication to offering groundbreaking, patient-centered care.
A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...
As one of the leading facilities for advanced neurological and Parkinson’s care in the region, King’s College Hospital Dubai ...
Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...
The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...
For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.
Jazz” by Harry Trumfio Judge’s comment: The beat of the music comes through in the rhythm of the poem. The metaphor of ...
It’s improving quality of life. Parkinson’s drugs are meant to keep patients in what’s called their “on state,” providing improvement in coordination and stiffness. But as the drugs wear off ...
"These findings in adults with Parkinson disease and motor fluctuations demonstrate the efficacy and acceptable safety profile of tavapadon as adjunctive therapy to levodopa," the authors write.